SARS-CoV-2 pathogenesis
- PMID: 35354968
- DOI: 10.1038/s41579-022-00713-0
SARS-CoV-2 pathogenesis
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a devastating pandemic. Although most people infected with SARS-CoV-2 develop a mild to moderate disease with virus replication restricted mainly to the upper airways, some progress to having a life-threatening pneumonia. In this Review, we explore recent clinical and experimental advances regarding SARS-CoV-2 pathophysiology and discuss potential mechanisms behind SARS-CoV-2-associated acute respiratory distress syndrome (ARDS), specifically focusing on new insights obtained using novel technologies such as single-cell omics, organoid infection models and CRISPR screens. We describe how SARS-CoV-2 may infect the lower respiratory tract and cause alveolar damage as a result of dysfunctional immune responses. We discuss how this may lead to the induction of a 'leaky state' of both the epithelium and the endothelium, promoting inflammation and coagulation, while an influx of immune cells leads to overexuberant inflammatory responses and immunopathology. Finally, we highlight how these findings may aid the development of new therapeutic interventions against COVID-19.
© 2022. Springer Nature Limited.
Similar articles
-
Acute respiratory distress syndrome: a life threatening associated complication of SARS-CoV-2 infection inducing COVID-19.J Biomol Struct Dyn. 2021 Oct;39(17):6842-6851. doi: 10.1080/07391102.2020.1803139. Epub 2020 Aug 5. J Biomol Struct Dyn. 2021. PMID: 32752936 Free PMC article. Review.
-
Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus.Front Cell Infect Microbiol. 2022 Mar 14;12:841447. doi: 10.3389/fcimb.2022.841447. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35360113 Free PMC article.
-
Replication of Severe Acute Respiratory Syndrome Coronavirus 2 in Human Respiratory Epithelium.J Virol. 2020 Jul 16;94(15):e00957-20. doi: 10.1128/JVI.00957-20. Print 2020 Jul 16. J Virol. 2020. PMID: 32434888 Free PMC article.
-
Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses.mBio. 2020 Dec 11;11(6):e03185-20. doi: 10.1128/mBio.03185-20. mBio. 2020. PMID: 33310781 Free PMC article.
-
Human and novel coronavirus infections in children: a review.Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25. Paediatr Int Child Health. 2021. PMID: 32584199 Review.
Cited by
-
A hybrid discrete-continuum model of immune responses to SARS-CoV-2 infection in the lung alveolar region, with a focus on interferon induced innate response.J Theor Biol. 2022 Dec 21;555:111293. doi: 10.1016/j.jtbi.2022.111293. Epub 2022 Oct 5. J Theor Biol. 2022. PMID: 36208668 Free PMC article.
-
Insight into designing of 2-pyridone derivatives for COVID-19 drug discovery - A computational study.Struct Chem. 2022 Oct 26:1-20. doi: 10.1007/s11224-022-02076-x. Online ahead of print. Struct Chem. 2022. PMID: 36320317 Free PMC article.
-
SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition.NPJ Vaccines. 2024 Feb 5;9(1):23. doi: 10.1038/s41541-024-00815-1. NPJ Vaccines. 2024. PMID: 38316833 Free PMC article.
-
Reversibility of the Enlargement of the Pulmonary Artery in COVID-19 Pneumonia as a Marker of Remission of the Disease.J Pers Med. 2024 Jan 31;14(2):161. doi: 10.3390/jpm14020161. J Pers Med. 2024. PMID: 38392595 Free PMC article.
-
SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity.Vaccines (Basel). 2024 Jul 18;12(7):795. doi: 10.3390/vaccines12070795. Vaccines (Basel). 2024. PMID: 39066432 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous